

Recombinant Human PTPMT1 Protein (His Tag)

Catalog Number: PKSH030769

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

| | |
|----------------------|---|
| Species | Human |
| Source | E.coli-derived Human PTPMT1 protein Lys 28-Thr 201, with an N-terminal His |
| Calculated MW | 21.7 kDa |
| Observed MW | 20 kDa |
| Accession | Q8WUK0-1 |
| Bio-activity | Measured by its ability to cleave pNPP. The specific activity is > 200 pmoles/min/μg. |

Properties

| | |
|-----------------------|--|
| Purity | > 94 % as determined by reducing SDS-PAGE. |
| Endotoxin | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, 10% glycerol, 1mM DTT, pH 7.5 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. |
| Reconstitution | Please refer to the specific buffer information in the printed manual. Please refer to the printed manual for detailed information. |

Data



> 94 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

PTPMT1 (PTP localized to the Mitochondrion 1) is a member of the protein tyrosine phosphatase superfamily that is localized exclusively to the mitochondrion. It has been recently reported that PTPMT1 dephosphorylates phosphatidylglycerol phosphate, an essential intermediate of cardiolipin biosynthesis. PTPMT1 deficiency in mouse embryonic fibroblasts compromises mitochondrial respiration and results in abnormal mitochondrial morphology. Lipid analysis of PTPMT1-deficient fibroblasts reveals an accumulation of PGP along with a concomitant decrease in phosphatidylglycerol. Modulation of mitochondrial ATP synthesis by PTPMT1 suggests a novel approach for the treatment of pancreatic cancers, which represent some of the deadliest forms of human tumors. The gluttony of cancer cells for energy is well established, and with the development of a modulator of expression, one may hope that we could also achieve the synthetic induction of PTPMT1 expression. It would then be expected that this effect would attenuate, if not abolish, the growth of pancreas-derived tumor cells and support the establishment of a novel regimen for pancreatic cancers.